Clearside Biomedical, Inc. (CLSDQ)
| Market Cap | 1.94M -96.7% |
| Revenue (ttm) | 3.33M -56.8% |
| Net Income | -26.00M |
| EPS | -5.05 |
| Shares Out | 5.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,413 |
| Average Volume | 46,970 |
| Open | 0.3021 |
| Previous Close | 0.3100 |
| Day's Range | 0.2110 - 0.3700 |
| 52-Week Range | 0.1101 - 14.0880 |
| Beta | 2.03 |
| RSI | 45.55 |
| Earnings Date | Mar 11, 2026 |
About Clearside Biomedical
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) ... [Read more]
Financial Performance
In 2024, Clearside Biomedical's revenue was $1.66 million, a decrease of -79.77% compared to the previous year's $8.23 million. Losses were -$34.35 million, 5.75% more than in 2023.
Financial StatementsNews
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
- Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector ® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations ...
Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
- Presentations Highlight the Versatility of Clearside's SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases -
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside's Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Micr...
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases -
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase ...
Clearside Biomedical Transcript: Stifel 2025 Virtual Ophthalmology Forum
The session highlighted advances in suprachoroidal drug delivery, growing clinical adoption, and the differentiated profile of CLS-AX for wet AMD. Phase III trials are designed for regulatory alignment and real-world relevance, with ongoing efforts to secure funding for further development.
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexibl...
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases Strong Clinical Evidence Supports Use of the Supra...
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the...
Clearside Biomedical Transcript: The Citizens JMP Life Sciences Conference 2025
Leaders in suprachoroidal drug delivery are advancing a phase III-ready asset for wet AMD, aiming for 3–6 month dosing intervals and leveraging strong phase II data. Phase III trials will align with real-world practice, with over 50% of patients expected to reach six-month intervals.
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference
ALPHARETTA, Ga., May 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...
Clearside Biomedical Transcript: 24th Annual Needham Virtual Healthcare Conference
The session highlighted advances in suprachoroidal drug delivery for retinal diseases, with a focus on the phase 3-ready CLS-AX for wet AMD and ongoing global partnerships. The company is optimizing trial design, expanding its pipeline, and actively seeking funding to support late-stage development.
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
Clearside Biomedical Earnings Call Transcript: Q4 2024
Positive phase II-B results for CLS-AX in wet AMD led to FDA alignment on pivotal phase III trials. Cash reserves fund operations into Q4 2025, with additional funding sought for phase III. Multiple global partnerships and regulatory milestones expand the suprachoroidal platform.
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner's New Drug Application for ARCATUS ® (XIPERE ®) for Uveitic Macular E...
Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
- Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases - - SCS Microinjector ® Provides Targeted and Compartmentalized Delivery of Therapeutics Dir...
Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit
- Post-Hoc Analyses Provide Comparative Data on Rescue Criteria and Intervention-Free Rates for Tyrosine Kinase Inhibitors (TKIs) in Wet AMD Development -
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025
ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to t...
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
- CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD - - Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Ty...
Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema
ALPHARETTA, Ga., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to th...
Clearside Biomedical Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025
The conference highlighted leadership in suprachoroidal drug delivery, with CLS-AX advancing to phase 3 for wet AMD after strong phase 2b results. Flexible dosing, safety, and strategic partnerships set the program apart, while pipeline expansion targets geographic atrophy with novel approaches.
Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting
- BCVA and CST Data from Sub-Group Analyses Provide Key Insights for Planned CLS-AX Phase 3 Trial Design - - BCVA and CST Data from Sub-Group Analyses Provide Key Insights for Planned CLS-AX Phase 3 T...
Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
ALPHARETTA, Ga., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s...
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program
- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial -